US 12,331,040 B2
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
Erkan Baloglu, Stoneham, MA (US); Sharon Shacham, Newton, MA (US); William Senapedis, Millis, MA (US); Dilara McCauley, Arlington, MA (US); Yosef Landesman, Brookline, MA (US); Gali Golan, Mesilat Zion (IL); Ori Kalid, Pardes Hanna (IL); and Sharon Shechter, Andover, MA (US)
Assigned to Karyopharm Therapeutics Inc., Newton, MA (US)
Filed by Karyopharm Therapeutics Inc., Newton, MA (US)
Filed on Mar. 18, 2021, as Appl. No. 17/205,797.
Application 17/205,797 is a continuation of application No. 16/507,927, filed on Jul. 10, 2019, granted, now 11,008,309.
Application 16/507,927 is a continuation of application No. 15/831,111, filed on Dec. 4, 2017, granted, now 10,399,963, issued on Sep. 3, 2019.
Application 15/831,111 is a continuation of application No. 14/902,202, granted, now 9,856,241, issued on Jan. 2, 2018, previously published as PCT/US2014/045479, filed on Jul. 3, 2014.
Claims priority of provisional application 61/975,171, filed on Apr. 4, 2014.
Claims priority of provisional application 61/904,843, filed on Nov. 15, 2013.
Claims priority of provisional application 61/879,070, filed on Sep. 17, 2013.
Claims priority of provisional application 61/842,856, filed on Jul. 3, 2013.
Prior Publication US 2021/0403459 A1, Dec. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 405/14 (2006.01); C07D 307/81 (2006.01); C07D 405/12 (2006.01); C07D 409/14 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 491/048 (2006.01); C07D 491/08 (2006.01)
CPC C07D 405/14 (2013.01) [C07D 307/81 (2013.01); C07D 405/12 (2013.01); C07D 409/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 491/048 (2013.01); C07D 491/08 (2013.01)] 31 Claims
 
1. A compound represented by Structural Formula V or VI:

OG Complex Work Unit Chemistry
R1a is selected from optionally substituted C6-C12 aryl and optionally substituted C5-C12 heteroaryl; and
R9a is optionally substituted aryl or optionally substituted heteroaryl;
R2 is optionally substituted aryl or optionally substituted heteroaryl;
m′ is 1 or 2;
or a pharmaceutically acceptable salt thereof.